Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Breast Cancer Clinical Trials

Review the breast cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 276-300 of 896

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Evaluation of Immune Cells and Response-Adapted Chemoimmunotherapy before Surgery for the Treatment of Triple-Negative Breast Cancer, The NeoTRACT Trial
Status: Active
Location: University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas
Capecitabine or Trastuzumab Emtansine with Radiation Therapy for the Treatment of High-Risk Stage I-IIIB Breast Cancer
Status: Active
Location: University of Virginia Cancer Center, Charlottesville, Virginia
Elacestrant Alone Compared to Elacestrant plus a CDK4/6 Inhibitor (Palbociclib, Abemaciclib, or Ribociclib) for Treating Patients with an ESR1 Mutation and ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Status: Active
Location: Northwestern University, Chicago, Illinois
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Sacituzumab Govitecan and Pembrolizumab Therapy before Surgery for the Treatment of Immunochemotherapy-Resistant Early-Stage Triple-Negative Breast Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tamoxifen Citrate or Aromatase Inhibitor in Treating Elderly Patients with Estrogen Receptor Positive Breast Cancer That Can Be Removed by Surgery
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
A Vaccine (Dendritic Cell 1) for the Treatment of Patients with HER-2 Positive Breast Cancer, NATASHA Study
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Neoadjuvant Neratinib for the Treatment of Stage I-III HER2-Mutated Lobular Breast Cancers
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Palbociclib and Pembrolizumab for the Treatment of Patients with Brain Metastases
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Comparison of Adjuvant Endocrine Therapy and Accelerated Partial Breast Irradiation following Lumpectomy for the Treatment of Early-Stage Breast Cancer Patients Over 65, CAMERAN Study
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Zanidatamab before Surgery for the Treatment of Early Stage HER2/Neu Positive Breast Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Vaccine (STEMVAC) with Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
A Sequential Treatment Plan for the Treatment of Hormone Positive Metastatic Breast Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Adaptive Therapy with Capecitabine for the Treatment of Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Status: Active
Location: Mayo Clinic in Arizona, Scottsdale, Arizona
Cemiplimab and Transarterial Radioembolization with Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Low Dose Capecitabine for the Treatment of Locally Advanced and Metastatic HER2 Negative Breast Cancer
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Neoadjuvant Letrozole with or without Abemaciclib in Hormone Receptor Positive Breast Cancer
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
5 versus 9-Day Course of Whole Breast Radiation Therapy for the Treatment of Early-Stage Breast Cancer in Patients Who Have Undergo Lumpectomy, FAST NOVEMBER Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Routine Cavity Shave Margins or Selective Shave Margins Using Savi Scout in Treating Stage I-II Invasive Breast Cancer or Stage 0 Breast Ductal Carcinoma in Situ
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Accelerated Super-Hypofractionated Breast Brachytherapy for Controlling Disease in Patients who have Undergone Lumpectomy for Breast Cancer, ASHBY Trial
Status: Active
Location: VCU Massey Comprehensive Cancer Center, Richmond, Virginia
Neoadjuvant Palbociclib in Combination with Endocrine Therapy for the Treatment of Patients with Early Stage Hormone Receptor Positive and HER2/neu Negative Breast Cancer
Status: Active
Location: University of Nebraska Medical Center, Omaha, Nebraska
Ultra Hypofractionated Whole Breast Radiation Therapy with Simultaneous Tumor Area Boost after Surgery for the Treatment of Early-Stage Breast Cancer, H-ASSIST Trial
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Fulvestrant and Neratinib, Alpelisib, Everolimus or Abemaciclib for the Treatment of Estrogen Receptor Positive HER2 Negative Metastatic or Locally Recurrent Breast Cancer Previously Treated with a CDK4/6 Inhibitor, GERTRUDE Trial
Status: Active
Location: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire